Antigenics to Present at Cowen & Company's Annual Health Care Conference.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Antigenics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AGEN) today announced that Garo H. Armen Garo H. Armen is chairman and chief executive officer of Antigenics Inc., the biotechnology company he cofounded with Pramod Srivastava in 1994. From mid-2002 through 2004, he was chairman of the board of directors for the biopharmaceutical company Elan Corporation plc. Dr. , PhD, the company's chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present at Cowen & Company's 27th Annual Health Care Conference at the Boston Marriott Copley Place at 3:15 p.m. ET on Tuesday, March 13. Antigenics, a biotech company with a market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. of approximately $80 million, is ideally positioned to benefit from the surging vaccine market, which is expected to double between 2004 to 2009 from $8 billion to $18 billion in sales.1 Dr. Armen will discuss how preventive and therapeutic vaccine development in multiple indications is creating new revenue opportunities for the company's vaccine adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. , QS-21 Stimulon([R]), and explain how Antigenics' collaborative partners and licensees - leaders in the vaccine field - are expected to be key drivers. The presentation will also outline potential commercial opportunities for Oncophage([R]) (vitespen) in kidney cancer, based on data obtained from its recently conducted, large Phase 3 randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. trial, in geographical territories outside the United States, including those in Russia, Europe and Canada. A clinical update on the study of Oncophage in recurrent glioma glioma /gli·o·ma/ (gli-o´mah) a tumor composed of neuroglia in any of its states of development; sometimes extended to include all intrinsic neoplasms of the brain and spinal cord, as astrocytomas, ependymomas, etc. will be provided as well. Dr. Armen will also review the company's Phase 1 priority development programs, which include AG-707 therapeutic vaccine for genital herpes infection and Aroplatin[TM] (L-NDDP) platinum agent for cancers. The audio portion of the presentation and the presentation slides will be webcast live and available subsequently by replay on the Cowen & Company website at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AGEN&item_id= 1493673. (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists). The replay of the webcast will begin approximately one hour after the live presentation and will be available for 90 days. The link to the audio replay and presentation slides will also be available on the Antigenics website, www.antigenics.com. Antigenics is a biotechnology company working to develop treatments for cancers and infectious diseases. 1Mercer Management Consulting Vaccine Report, 2006. This press release contains forward-looking statements, including statements regarding the potential future growth of the vaccine market and its impact on the company; and revenue opportunities for the company. These risks and uncertainties include, among others, decisions by collaborative partners and licensees; decisions by regulatory agencies; timing and results of clinical and preclinical studies; timely and successful development of QS-21 manufacturing capabilities; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis Management's discussion and analysis (MD&A) A report from management to shareholders that accompanies the firm's financial statements in the annual report. It explains the period's financial results and enables management to discuss topics that may not be apparent in the financial of Financial Condition and Results of Operations section of Antigenics' Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2006. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion